# Brigitte C. Widemann

Source: https://onco.cc/people/brigitte-widemann/  
OnCo record `brigitte-widemann` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the selumetinib trials that gave children with neurofibromatosis their first approved drug.

## Summary

Brigitte C. Widemann is Chief of the Pediatric Oncology Branch and Special Advisor to the NCI Director for Childhood Cancer at the National Cancer Institute. She is a paediatric oncologist known for the neurofibromatosis type 1 plexiform neurofibroma studies that led to selumetinib's approval, the first approved drug for children with the condition. Her selected paper reports selumetinib in children with inoperable plexiform neurofibromas. She now leads NCI's paediatric oncology branch and its rare tumour initiatives, with interests spanning neuroblastoma and sarcomas.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief, Pediatric Oncology Branch; Special Advisor to the NCI Director for Childhood Cancer
- Specialisms: Paediatric oncology; Neurofibromatosis; MEK inhibitors

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Brigitte_C._Widemann
- NCI CCR profile: https://ccr.cancer.gov/staff-directory/brigitte-c-widemann
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Widemann%20BC%5BAuthor%5D

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [NCI Center for Cancer Research (intramural programme)](https://onco.cc/institutions/nci-ccr/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)

---
JSON: https://onco.cc/api/v1/entities/brigitte-widemann.json